Skip to content
Clinical Trials – home
CroatiaBack to Croatia

Clinical trials in Cepin – page 7

88 clinical trials in Cepin, Croatia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CroatiaOur site in CroatiaKlinicka-Ispitivanja.hr(opens in a new tab)
Cepin at a glance
88
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

88 trials in Cepin

Open in trial search

Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Opthea Limited

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness and Safety of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Hepatic cirrhosis

Not recruiting

Study on the Effects of Human Serum Albumin on Survival in Patients with Severe Acute-On-Chronic Liver Failure

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Human Serum Albumin
  • Sponsor:Instituto Grifols S.A.

Study Comparing RBS-001 and Aflibercept for Patients with Neovascular Age-Related Macular Degeneration

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Rophibio Inc.

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Constipation

Not recruiting

Study on Linaclotide for Treating Functional Constipation in Children Aged 6 Months to Less Than 2 Years

Registered drug
Countries:CroatiaCroatia
  • Participants:0–17 years
  • Substances:Linaclotide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative

Not recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Study on the Safety of Avacincaptad Pegol for Patients with Geographic Atrophy Who Completed a Previous Study

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Avacincaptad Pegol
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Croatia

The busiest research cities in the country

All 26 cities in Croatia

Clinical research in Cepin

What the registry says about research in the country

01 Cardiovascular Diseases

Clinical trial activity in Cepin is focused entirely on cardiovascular diseases, with studies exploring new ways to reduce heart-related events and improve long-term outcomes for people living with complex heart conditions.

  • Chronic heart failure
  • Heart failure with mildly reduced or preserved ejection fraction
  • Heart failure with reduced ejection fraction
  • Heart condition

These trials are mainly testing whether newer treatments can better control inflammation, protect the heart, and lower the risk of hospitalization or cardiovascular death.

02 Heart Failure and Inflammation

Several studies are examining heart failure together with systemic inflammation, aiming to see whether targeted therapy can improve outcomes for patients with HFmrEF and HFpEF.

  • HFmrEF
  • HFpEF
  • Systemic inflammation
  • Cardiovascular death and heart failure events

This research is designed to evaluate a potential new treatment approach for people whose heart failure is linked with inflammatory activity.

03 Heart Failure Treatment Options

Another important area of research is the management of heart failure in patients who cannot use standard mineralocorticoid receptor antagonists, with studies looking at both effectiveness and safety.

  • HFrEF
  • Finerenone
  • Safety and tolerability
  • Standard heart failure care

These trials are intended to expand treatment options for people with limited access to current therapies.

04 Diabetes, Hypertension, and Cardiovascular Risk

Research in the city also includes patients with type 2 diabetes, hypertension, and established cardiovascular disease, reflecting the close link between metabolic and heart health.

  • Type 2 diabetes
  • High blood pressure
  • Established cardiovascular disease
  • Heart-related hospital visits

These studies are focused on whether combining therapies can better prevent serious cardiovascular events in high-risk patients.

05 Iron Deficiency in Chronic Heart Failure

One trial is exploring whether treating iron deficiency in people with symptomatic chronic heart failure can improve survival and reduce worsening heart failure.

  • Symptomatic chronic heart failure
  • Iron deficiency
  • Ferric derisomaltose
  • Hospitalization prevention

This line of research aims to clarify the role of iron replacement as part of comprehensive heart failure care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.